FEMY · XBRL financial data

Femasys financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (FEMY's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1,180	1,206	1,072	1,629	2,293
Cost of goods and services sold	370	442	380	545	872
Gross profit	809	764	—	—	—
Research and development	4,084	5,814	7,209	8,217	7,578
General and administrative	4,262	5,431	6,858	6,326	6,646
Total operating expenses	9,146	12,365	15,200	18,870	19,010
Operating income (loss)	(8,337)	(11,600)	(14,508)	(17,786)	(17,589)
Interest income	—	—	431	582	102
Interest expense	19	13	165	1,604	1,891
Other income (expense)	—	—	—	0	(483)
Income tax expense (benefit)	4	6	4	10	1
Net income (loss)	(7,538)	(11,394)	(14,247)	(18,817)	(18,628)
Earnings per share, basic‡ USD per share	(22.40)	(19.20)	(18.60)	(17.00)	(9.40)
Earnings per share, diluted‡ USD per share	(22.40)	(19.20)	(18.60)	(17.00)	(9.40)
Weighted average shares, basic‡ thousands of shares	336	591	769	1,113	1,977
Weighted average shares, diluted‡ thousands of shares	336	591	769	1,113	1,977

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2026); filings made before it reported them unadjusted.

Fiscal years (FEMY's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	24,783	12,962	21,716	3,452	9,266
Accounts receivable	84	77	99	488	617
Inventory	208	437	667	3,046	5,740
Total current assets	25,631	14,131	23,178	8,022	16,456
Property and equipment, net	1,599	1,483	1,111	1,596	1,896
Right-of-use asset	636	308	2,380	1,806	1,297
Total assets	28,577	16,896	27,756	12,445	20,724
Accounts payable	446	511	1,138	1,419	1,830
Accrued liabilities	604	457	1,444	1,151	1,266
Total current liabilities	1,692	1,528	3,054	8,583	3,636
Lease liability, non-current	386	29	2,036	1,518	1,030
Total liabilities	2,244	1,653	9,403	10,141	14,855
Accumulated deficit	(82,740)	(94,135)	(108,382)	(127,198)	(145,826)
Total stockholders' equity	26,332	15,243	18,353	2,304	5,869
Total liabilities and equity	28,577	16,896	27,756	12,445	20,724
Common shares outstanding (cover page)‡ thousands of shares	590	594	1,105	1,357	3,020

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2026); filings made before it reported them unadjusted.

Fiscal years (FEMY's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(7,538)	(11,394)	(14,247)	(18,817)	(18,628)
Stock-based compensation	193	225	676	444	790
Net cash from operating activities	(7,931)	(10,732)	(11,281)	(19,444)	(18,691)
Purchases of property and equipment	307	407	144	762	525
Net cash from investing activities	(307)	(407)	(144)	(848)	(630)
Proceeds from issuing common stock	31,740	79	7,665	2,025	—
Share repurchases	—	0	230	61	—
Net cash from financing activities	29,698	(682)	20,179	2,027	25,135

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Femasys	1,444	332	(3,936)*	8.4M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
DarioHealth	6,634	not reported	(6,083)*	9.8M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Cerenome	2,366	411	(7,132)*	7.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
electroCore	8,501	9,450	(3,518)*	9.0M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
QT Imaging Holdings	10,924	7,435	(4,837)*	14.6M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Nephros	4,697	6,017	681*	10.9M	—	Q2 FY26 10-QJun 30, 2026
RenovoRx	9,479	909	(2,867)*	45.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Precision Optics	9,841	8,774*	(649)*	11.0M	15.2 quarters	Q4 FY26 10-KJun 30, 2026
Neuroone Medical Technologies	2,048	1,973	(1,082)*	9.1M	1.9 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.